Based on moderate quality evidence , due to concerns about risk of bias and imprecision , initiation of statin therapy within 14 days following ACS does not reduce death , myocardial infa rct ion , or stroke up to four months , but reduces the occurrence of unstable angina at four months following ACS .
Serious side effects were rare
BACKGROUND The early period following the onset of acute coronary syndrome ( ACS ) represents a critical stage of coronary heart disease , with a high risk of recurrent events and deaths .
The short-term effects of early treatment with statins on patient-relevant outcomes in patients suffering from ACS are unclear .
This is an up date of a review previously published in 2011 .
OBJECTIVES To assess the effects , both harms and benefits , of early administered statins in patients with ACS , in terms of mortality and cardiovascular events .
Intensive-Dose Atorvastatin Regimen Halts Progression of Atherosclerotic Plaques in New-onset Unstable Angina With Borderline Vulnerable Plaque Lesions
To compare the therapeutic effects of intensive versus moderate dosage of atorvastatin regimens in new-onset unstable angina with borderline lesions , 100 patients were r and omized to receive either 80 mg/d or 20 mg/d atorvastatin for 9 months . Clinical symptoms , lipid profiles , and coronary stenosis ( evaluated by coronary angiography and intravascular ultrasound ) were compared to their corresponding baselines within each group and between the 2 groups after 9 months of treatment . The results showed that ( 1 ) when compared to their corresponding baselines , both groups exhibited improvement in clinical symptoms , a significant decrease in total cholesterol , triglyceride , low-density lipoprotein cholesterol ( LDL-C ) , and high-sensitivity C-reactive protein ( hs-CRP ; P < .01 ) and a significant increase in high-density lipoprotein cholesterol ( HDL-C ) ; ( 2 ) the improvement in clinical symptoms and the decrease in LDL-C and hs-CRP were significantly greater ( P < .01 ) in the intensive-dose group than in the moderate-dose group ; ( 3 ) the mean plaque volume did not progress in the intensive-dose group but increased significantly ( P < .05 ) in the moderate-dose group . We conclude that compared to the moderate dose , the intensive-dose regimen significantly improves clinical symptoms , lowers LDL-C and hs-CRP , and halts the progression of borderline atherosclerotic plaques in patients with new-onset unstable angina
Based on moderate quality evidence , due to concerns about risk of bias and imprecision , initiation of statin therapy within 14 days following ACS does not reduce death , myocardial infa rct ion , or stroke up to four months , but reduces the occurrence of unstable angina at four months following ACS .
Serious side effects were rare
BACKGROUND The early period following the onset of acute coronary syndrome ( ACS ) represents a critical stage of coronary heart disease , with a high risk of recurrent events and deaths .
The short-term effects of early treatment with statins on patient-relevant outcomes in patients suffering from ACS are unclear .
This is an up date of a review previously published in 2011 .
OBJECTIVES To assess the effects , both harms and benefits , of early administered statins in patients with ACS , in terms of mortality and cardiovascular events .